BTC Capital Management Inc. increased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 70,033 shares of the company’s stock after acquiring an additional 1,012 shares during the quarter. Johnson & Johnson makes up 1.4% of BTC Capital Management Inc.’s investment portfolio, making the stock its 13th largest position. BTC Capital Management Inc.’s holdings in Johnson & Johnson were worth $9,070,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds also recently bought and sold shares of the company. Virtus ETF Advisers LLC bought a new position in Johnson & Johnson during the 2nd quarter worth approximately $25,000. Krane Funds Advisors LLC bought a new position in Johnson & Johnson during the 2nd quarter worth approximately $26,000. Crewe Advisors LLC grew its position in shares of Johnson & Johnson by 725.9% in the 2nd quarter. Crewe Advisors LLC now owns 223 shares of the company’s stock worth $31,000 after buying an additional 196 shares during the last quarter. Permanens Capital L.P. grew its position in shares of Johnson & Johnson by 50.0% in the 2nd quarter. Permanens Capital L.P. now owns 300 shares of the company’s stock worth $42,000 after buying an additional 100 shares during the last quarter. Finally, Personal Wealth Partners bought a new stake in shares of Johnson & Johnson in the 2nd quarter worth approximately $73,000. Institutional investors and hedge funds own 72.05% of the company’s stock.
A number of brokerages have recently weighed in on JNJ. Bank of America reiterated a “hold” rating and issued a $150.00 price objective on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Goldman Sachs Group set a $169.00 price objective on Johnson & Johnson and gave the stock a “buy” rating in a research report on Tuesday, August 27th. Sanford C. Bernstein upgraded Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $155.00 price objective on the stock in a research report on Friday, October 11th. Wells Fargo & Co cut their price objective on Johnson & Johnson from $157.00 to $155.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 16th. Finally, Raymond James cut their price objective on Johnson & Johnson from $146.00 to $145.00 and set an “outperform” rating on the stock in a research report on Monday, October 14th. Six research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Johnson & Johnson currently has a consensus rating of “Buy” and a consensus target price of $151.18.
Shares of JNJ stock opened at $127.70 on Monday. The firm has a market cap of $359.38 billion, a P/E ratio of 15.61, a P/E/G ratio of 2.30 and a beta of 0.69. Johnson & Johnson has a fifty-two week low of $121.00 and a fifty-two week high of $148.99. The business’s 50 day moving average price is $130.45 and its 200-day moving average price is $134.76. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.04 and a current ratio of 1.33.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 15th. The company reported $2.12 EPS for the quarter, beating the Zacks’ consensus estimate of $2.00 by $0.12. The company had revenue of $20.73 billion during the quarter, compared to analysts’ expectations of $20.14 billion. Johnson & Johnson had a return on equity of 39.54% and a net margin of 21.09%. The firm’s revenue for the quarter was up 1.9% compared to the same quarter last year. During the same quarter last year, the business posted $2.05 EPS. As a group, equities analysts predict that Johnson & Johnson will post 8.65 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be paid a $0.95 dividend. This represents a $3.80 dividend on an annualized basis and a dividend yield of 2.98%. The ex-dividend date is Monday, November 25th. Johnson & Johnson’s payout ratio is presently 46.45%.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Article: Why Net Income is Important to Investors
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.